Navigation Links
Groundbreaking UK Study Confirms Significant Reduction in Hospital Superbug Pathogens with TRU-D SmartUVC Disinfection Robot
Date:7/18/2013

NOTTINGHAM, England, July 18, 2013 /PRNewswire/ -- A recent study titled "First UK evaluation of an automated ultraviolet-C room decontamination device (TRU-D™)" confirms the effectiveness of TRU-D SmartUVC™ in eliminating common superbugs in health care environments.

The study was conducted by the Department of Clinical Microbiology and Infection Prevention and the Control Department at Nottingham University Hospitals NHS Trust's QMC campus in Nottingham, England, and was published in the Journal of Hospital Infection (N. Mahida, et al., 2013). The research concluded that when delivering a measured and consistent UV-C dose in a cleaned, unoccupied patient room, TRU-D reduced MRSA, MRA and VRE pathogens by 99.99 percent. Additionally, the study complements the ease of use and transporting the device, as well as its rapid disinfection time.

TRU-D was the only device utilized in the study. Short for Total Room Ultraviolet Disinfector, TRU-D – the signature product of Memphis-based Lumalier – is the only portable UV disinfection system on the market that precisely measures reflected UV-C emissions with Sensor360™ to automatically calculate the pathogen-lethal UV dose required for proper and consistent disinfection of health care environments. A proper dose of UV-C light modifies the DNA structure of an infectious cell so it cannot reproduce and therefore cannot colonize and spread.

After a hospital room is cleaned using traditional methods, TRU-D is rolled into the room to "finish the job." Setup is fast and easy and does not require input of room measurements or covering of windows and vents. The machine is turned on from outside the room using a handheld remote. From a single placement near the center of the room, its patented Sensor360™ technology instantly analyzes the unique contents, shape and size of the room, then floods the targeted space (both line-of-site and shadowed spaces) with the proper dose of germicidal energy. TRU-D spends whatever time is necessary (usually 20 to 35 minutes) to confidently eliminate infectious germs from contaminated surfaces before shutting down and audibly notifying the operator that disinfection is complete.    

In this UK study, TRU-D was used in six side-rooms in Nottingham University Hospital NHS Trust's QMC campus' intensive therapy unit, an operating theater and a ward isolation room with an in-suite bathroom. The device was placed in the middle of the room, and contact plates inoculated with clinical strains of MRSA, MRA, VRE and aspergillus were placed on 15 touch surfaces in both direct and indirect (shadowed) line of sight of TRU-D. After one disinfection cycle, the plates were then reapplied to surfaces directly adjacent to the original plate locations. The study specifically notes TRU-D's capability "to significantly reduce key health care nosocomial pathogens (MRSA, VRE, MRA) in the hospital environment," including the operating theatre; and that advantages include the device's simplicity and limited training needed by staff to operate TRU-D.

Studies show that 50 percent or more of hospital surfaces go untouched during terminal room disinfection.  The Centers for Disease Control and Prevention reports that health care-associated infections are tied to an estimated 99,000 deaths in the USA each year and represent an estimated $30 billion a year in medical costs. Recently, the European Centre for Disease Prevention and Control released its first point prevalence survey, which reported that on any given day, about 80,000 patients -- or one in 18 patients -- in European hospitals have acquired at least one health care-associated infection.

"Health care leaders around the world are recognizing the importance of adding automated no-touch disinfection technology to comprehensive manual cleaning routines already in place," said Chuck Dunn, president of Lumalier. "TRU-D is being used in hundreds of hospitals around the U.S. and Canada, and we will continue to expand our science-based market leadership in the UK."

            For information, visit www.TRU-D.com.

 

For more information, contact:

Lauren Hannaford

Obsidian Public Relations

Phone: 901-572-1042

Email

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE TRU-D LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epilepsy Foundation Launches The "Epilepsy Innovation Seal Of Excellence" Recognizing Groundbreaking Product Candidates For People With Epilepsy
2. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
3. Babys life saved with groundbreaking 3D printed device from U-M that restored his breathing
4. Thousands Of Cats With Kidney Disease Sought For Groundbreaking Clinical Trial
5. Premier Cancer Centers Dallas opens up a new world of groundbreaking and life-saving technology
6. Mayor Greg Ballard to Join Roche Diagnostics Leaders at Groundbreaking of New Learning and Development Center
7. Richard Wolf Medical Instruments introduces groundbreaking 5514 Endocam Performance HD
8. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
9. Study Estimates that 4.3 Million Prescriptions for Painkillers Were Diverted to Illicit Use by "Doctor Shoppers"
10. DART Therapeutics Initiates Study of HT-100 For Duchenne Muscular Dystrophy
11. RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer Plotting ... for fluorescence microscopists and optical system designers, enabling The Right Solution, Right Now. ... globe, SearchLight has become a tremendously popular tool for the fluorescence imaging community” ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... Economics Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis ... (IRR) field. Offering practical takeaways to apply immediately to IRR programs, the report ...
(Date:4/27/2017)... Minneapolis, Minnesota (PRWEB) , ... April 27, 2017 ... ... Smith and her husband Dan Gasby the 2017 Public Leadership in Neurology Award ... Bob Woodruff, retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael ...
(Date:4/27/2017)... ... 27, 2017 , ... Goodcents Deli Fresh Subs announced a franchise expansion agreement ... year. , The first new location will open at the corner of 27th ... and Northern Lights Drive this fall. And the third location is in the process ...
(Date:4/27/2017)... ... April 27, 2017 , ... Plastic Surgery Associates is excited to announce ... present at the upcoming Aesthetic Meeting. Held in San Diego, at the San Diego ... Canales will lend their expertise to the Premier Global Hot Topics session, speaking on ...
Breaking Medicine News(10 mins):